Table 2.
MicroRNAs commonly affected in cancer and their targets
| MicroRNA | Oncogene or tumor suppressor | Cancer types | Key targets (and their functions) |
|---|---|---|---|
| miR-17 ~ 92 cluster [19-36] |
OG/TS |
Lung, breast, pancreas, colon, BCL, retinoblastoma, glioblastoma |
HIF-1α (hypoxia response) |
| PTEN, E2F1-3, TNF-α, RAB14 (cell proliferation) | |||
| BIM, TGFBR2 (cell survival) | |||
| TSP1, CTGF (tumor angiogenesis) | |||
| miR-21 [37-53] |
OG |
Lung, breast, lymphoma, glioblastoma |
PTEN, SPRY1, SPRY2, (cell proliferation) |
| PDCD4, APAF1 (cell survival) | |||
| TPM-1, TPM-3, RECK (metastasis) | |||
| miR-155 [26,42,54-61] |
OG |
Lung, lymphoma, breast |
FOXO3A, SHIP1, SOCS1 (cell survival) |
| RhoA (metastasis) | |||
| miR-221 or miR-222 [45,62-67] |
OG |
Lung, glioblastoma |
KIT, p27, PUMA (cell survival) |
| PTEN (cell proliferation) | |||
|
let-7[68,69,78-83] |
TS |
Lung, lymphoma, gastric, prostate, breast, ovarian |
KRAS, NRAS, CDC25A, c-MYC (cell proliferation) |
| HMGA2 (metastasis) | |||
| miR-34 [84-88,91-93] |
TS |
Lung, lymphoma, pancreas, colon, neuroblastoma, glioblastoma |
CDC25A, CDK4, CDK6, c-MYC (cell proliferation) |
| MET (metastasis) | |||
| BCL2 (cell survival) | |||
| miR-15/16 [94-98] |
TS |
CLL, multiple myeloma, prostate, pancreas |
BCL2 (cell survival) |
| CDC2, JUN, FGF-2, CCND-1 (cell proliferation) | |||
| miR-200 [99-102] |
TS |
Breast, renal, gastric, bladder |
ZEB1, ZEB2 (cell differentiation and metastasis) |
| miR-181 [103,104] |
TS |
Glioma, lymphoma |
TCL1 (cell survival) |
| miR-29 [105-112] |
TS |
CLL, hepatocellular carcinoma, breast |
MCL1, TCL1 (cell survival) |
| DNMT1 (gene expression) |
BCL, B-cell lymphoma; CLL, chronic lymphocytic leukemia; OG, oncogene; TS, tumor suppressor.